Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Neurocrine Biosciences Inc Market Cap
Based on ratings from 13 stock analysts, the Neurocrine Biosciences Inc stock price is expected to increase by 47.3% in 12 months. This is calculated by using the average 12-month stock price forecast for Neurocrine Biosciences Inc. The lowest target is $128 and the highest is $204. Please note analyst price targets are not guaranteed and could be missed completely.
NBIX is a stock in Healthcare which has been forecasted to be worth $167.92 as an average. On the higher end, the forecast price is $204 USD by from and on the lower end NBIX is forecasted to be $128 by Neena Bitritto-Garg from Citigroup.
These are the latest 20 analyst ratings of NBIX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Charles Duncan Cantor Fitzgerald | Overweight | $155 | Reiterates | Sep 16, 2024 |
| Carter Gould Barclays | Overweight | $160 | Maintains | Sep 9, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $136 | Maintains | Aug 29, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $190 | Reiterates | Aug 29, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $155 | Maintains | Aug 29, 2024 |
| Evan Seigerman BMO Capital | Market Perform | $128 | Maintains | Aug 29, 2024 |
| Ami Fadia Needham | Hold | Reiterates | Aug 29, 2024 | |
| David Amsellem Piper Sandler | Overweight | $159 | Upgrade | Aug 29, 2024 |
| Akash Tewari Jefferies | Buy | $189 | Maintains | Aug 19, 2024 |
| Anupam Rama JP Morgan | Overweight | $181 | Maintains | Aug 7, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $190 | Maintains | Aug 5, 2024 |
| Jay Olson Oppenheimer | Outperform | $219 | Maintains | Aug 2, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $143 | Maintains | Aug 2, 2024 |
| Carter Gould Barclays | Overweight | $180 | Maintains | Aug 2, 2024 |
| Yatin Suneja Guggenheim | Buy | $180 | Maintains | Aug 2, 2024 |
| David Hoang Citigroup | Neutral | $158 | Maintains | Aug 2, 2024 |
| Brian Skorney Baird | Outperform | $180 | Maintains | Aug 2, 2024 |
| Ami Fadia Needham | Hold | Reiterates | Aug 1, 2024 | |
| Ami Fadia Needham | Hold | Reiterates | Jul 25, 2024 | |
| Charles Duncan Cantor Fitzgerald | Overweight | $155 | Reiterates | Jul 25, 2024 |
When did it IPO
1996
Staff Count
1,500
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Kevin C. Gorman Ph.D.
Market Cap
$11.28B
In 2023, NBIX generated $1.89B in revenue, which was a increase of 26.76% from the previous year. This can be seen as a signal that NBIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences announced interim results from the KINECT®-HD2 trial of INGREZZA® for Huntington's disease chorea, presented at the 2024 MDS Congress.
Why It Matters - The interim results from the KINECT®-HD2 trial may indicate potential market expansion for Neurocrine Biosciences' INGREZZA®, affecting stock performance and investor confidence in the company's growth prospects.
Thu, 19 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit on September 19, 2024, at 11:00 a.m.
Why It Matters - Neurocrine's participation in a key neuropsychiatry summit highlights its ongoing engagement in innovative research, potentially impacting stock performance and investor interest.
Thu, 12 Sep 2024
Sentiment - NEGATIVE
Source - Reuters
Summary - Neurocrine Biosciences reported that its experimental drug failed to meet the primary endpoint in a mid-stage trial for enhancing cognitive function in schizophrenia patients.
Why It Matters - Failure in the mid-stage trial raises concerns about the drug's viability, potentially impacting Neurocrine Biosciences' stock value and future revenue projections.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences' Phase 2 study of luvadaxistat for schizophrenia cognitive impairment failed to meet its primary endpoint. The company will shift focus to Phase 3 developments for other treatments.
Why It Matters - The failure of Luvadaxistat's Phase 2 study may lead to decreased investor confidence in Neurocrine Biosciences, impacting stock performance and future funding for other projects.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2024 Cantor Global Healthcare Conference in New York on September 10, 2024, at 3:05 p.m.
Why It Matters - Neurocrine's participation in a key healthcare conference may indicate upcoming announcements or partnerships, impacting stock performance and investor sentiment.
Sun, 01 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Nxera Pharma (TSE 4565) will receive a $35 million payment from Neurocrine Biosciences following successful Phase 2 trial results for NBI-1117568 in schizophrenia, to be recorded as Q3 2024 revenue.
Why It Matters - Nxera Pharma's receipt of a $35 million payment due to a successful drug trial enhances its cash position and may boost investor confidence in its growth potential and financial stability.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
